605177.SH
东亚药业
SSE · Healthcare · Biotechnology · CN
CNY 20.64
−0.43%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 940.2M | 1.2B | 1.4B | 1.2B |
| Cost of Revenue | 802.9M | 718.1M | 865.7M | 995.1M | 910.4M |
| Gross Profit | 211.0M | 222.1M | 332.6M | 361.4M | 269.2M |
| Operating Expenses | |||||
| R&D Expense | 84.6M | 86.8M | 117.0M | 81.7M | 44.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 164.0M | 161.1M | 170.3M | 137.2M | 116.7M |
| Selling & Marketing Expense | 14.1M | 12.8M | 15.4M | 13.8M | 9.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 298.7M | 285.3M | 308.0M | 234.8M | 165.6M |
| Cost and Expenses | 1.1B | 1.0B | 1.2B | 1.2B | 1.1B |
| Operating Income (EBIT) | (111.7M) | (84.6M) | (101.7M) | 137.0M | 120.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (116.2M) | (88.6M) | (118.2M) | 134.7M | 115.1M |
| Income Tax Expense | (5.5M) | (6.1M) | (17.5M) | 13.4M | 10.7M |
| Bottom Line | |||||
| Net Income | (110.7M) | (82.4M) | (100.7M) | 121.2M | 104.4M |
| Earnings from Cont. Ops | (110.7M) | (82.4M) | (100.7M) | 121.2M | 104.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (110.7M) | (82.4M) | (100.7M) | 121.2M | 104.4M |
| Per Share | |||||
| Basic EPS | (CN¥0.96) | (CN¥0.72) | (CN¥0.90) | CN¥1.07 | CN¥0.92 |
| Diluted EPS | (CN¥0.96) | (CN¥0.48) | (CN¥0.69) | CN¥0.97 | CN¥0.92 |
| Revenue Per Share | CN¥8.93 | CN¥8.22 | CN¥10.71 | CN¥11.97 | CN¥10.39 |
| Shares | |||||
| Basic Shares Outstanding | 113.6M | 114.4M | 111.8M | 113.3M | 113.5M |
| Diluted Shares Outstanding | 113.6M | 114.4M | 111.8M | 113.3M | 113.5M |
| Profitability Metrics | |||||
| EBITDA | — | 71.4M | 34.0M | 247.3M | 214.2M |
| D&A | — | 156.0M | 135.7M | 110.4M | 93.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026